GI SLIDE DECK 2016 Selected abstracts on Colorectal Cancer from:

18th World Congress on Gastrointestinal Cancer 29 June–2 July 2016 | Barcelona, Spain



Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this publication



Letter from ESDO

DEAR COLLEAGUES

It is my pleasure to present this ESDO slide set which has been designed to highlight and summarise key findings in digestive cancers from the major congresses in 2016. This slide set specifically focuses on the **18th World Congress on Gastrointestinal Cancer 2016** and is available in English and Japanese.

The area of clinical research in oncology is a challenging and ever changing environment. Within this environment, we all value access to scientific data and research that helps to educate and inspire further advancements in our roles as scientists, clinicians and educators. I hope you find this review of the latest developments in digestive cancers of benefit to you in your practice. If you would like to share your thoughts with us we would welcome your comments. Please send any correspondence to <u>info@esdo.eu</u>. Finally, we are also very grateful to Lilly Oncology for their financial, administrative and logistical support

in the realisation of this activity.

Yours sincerely,

Eric Van Cutsem Wolff Schmiegel Phillippe Rougier Thomas Seufferlein (ESDO Governing Board)



european society of digestive oncology

ESDO Medical Oncology Slide Deck Editors 2016

COLORECTAL CANCERS

Prof Eric Van Cutsem	Digestive Oncology, University Hospitals, Leuven, Belgium
Prof Wolff Schmiegel	Department of Medicine, Ruhr University, Bochum, Germany
Prof Thomas Gruenberger	Department of Surgery I, Rudolf Foundation Clinic, Vienna, Austria

PANCREATIC CANCER AND HEPATOBILIARY TUMOURS

Prof Jean-Luc Van Laethem Digestive Oncology, Erasme University Hospital, Brussels, Belgium **Prof Thomas Seufferlein** Clinic of Internal Medicine I, University of Ulm, Ulm, Germany

GASTRO-OESOPHAGEAL AND NEUROENDOCRINE TUMOURS

Emeritus Prof Philippe Rougier University Hospital of Nantes, Nantes, France **Prof Côme Lepage** University Hospital & INSERM, Dijon, France

BIOMARKERS

Prof Eric Van Cutsem Digestive Oncology, University Hospitals, Leuven, Belgium **Prof Thomas Seufferlein** Clinic of Internal Medicine I, University of Ulm, Ulm, Germany











Glossary

1L 2L 3L 5FU AE ARCAD BMI BSC Cap cfDNA CI CR (m)CRC CRM CRTx CT ctDNA D DCR (m)DOR ECOG EGFR EMS EORTC-QLQC30 FFPE FOLFIRI FOLFIRINOX/ FOLFOXIRI FOLFOXIRI FOLFOXIRI FOLFOXIRI FOLFOXIRI FOLFOXIRI FOLFOX GemCap H&E HR IC IHC IL IQR ITT IV KRASmt LARC LDH LP-LA	first line second line third line 5-fluorouracil adverse event Aide et Recherche en Cancérologie Digestive body mass index best supportive care capecitabine cell-free DNA confidence interval complete response (metastatic) colorectal cancer circumferential resection margin conventional radiochemotherapy chemotherapy circulating DNA day disease control rate median duration of response Eastern Cooperative Oncology Group endothelial growth factor receptor extramural tumour spread European Organization for Research and Treatment of Cancer core quality of life questionnaire formalin-fixed, paraffin-embedded leucovorin, fluorouracil, irinotecan leucovorin, fluorouracil, oxaliplatin emcitabine, capecitabine haematoxylin and eosin hazard ratio immunohistochemistry interleukin interquartile range intent-to-treat intravenous KRAS mutant locally advanced rectal cancer lactate dehydrogenase left posterior-left anterior	MRI MSI-H MSS MUT NA NE NGS NR ORR ORR ORR ORR ORR ORR ORR ORR OR PD-L1 PFR PD PD-L1 PFR PD PD-L1 PFR PD PD-L1 PFR PD PD PD-L1 PFR PD PD PD PD PD PD PD PD PD PD PD PD PD	magnetic resonance imaging microsatellite instability microsatellite instability high microsatellite stable mutant not available not estimable next generation sequencing not reached odds ratio overall response rate (median) overall survival oxaliplatin (quantitative) polymerase chain reaction progressive disease programmed death-ligand 1 progression-free rate (median) progression-free survival pharmacodynamic pharmacodynamic pharmacodynamic pharmacokinetic by mouth partial response performance status every 2 weeks every week quality of life randomised Response Evaluation Criteria In Solid Tumors recurrence-free survival receiver operating characteristic radiotherapy serious adverse event squamous cell carcinoma of the anus short-course radiotherapy + consolidation chemotherapy stable disease selective internal radiation therapy sum of longest diameter single-nucleotide polymorphism standard of care tumour cells World Health Organization wild type oxaliplatin, capecitabine
---	--	---	--

Contents


Colorectal cancer	<u>6</u>
 Screening, biomarkers and prognostic markers 	<u>30</u>
Colon cancer	<u>55</u>
Rectal cancer	<u>59</u>
Anal cancer	<u>71</u>

COLORECTAL CANCER

LBA-01: Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC) – Bendell J, et al

Study objective

• To evaluate the efficacy and safety of cobimetinib (MEK inhibitor) combined with atezolizumab (anti-PD-L1) in patients with mCRC



Dose-expansion stage phase

Cobimetinib 60 mg/day PO + Atezolizumab 800 IV q2w (n=20 [all KRASmt])

ENDPOINTS

- Safety
- ORR, mDOR, mPFS, mOS, 6 month OS

Bendell J, et al. Ann Oncol 2016; 27 (suppl 2): abstr LBA-01

LBA-01: Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC) – Bendell J, et al


Key results

Patients with CRC (n=23)	Treatment-related, n (%)
Grade 3 AEs	8 (35)
Grade 4/5 AEs	0 (0)
Serious AEs	2 (9)
AEs leading to withdrawal from cobimetinib	4 (17)
AEs leading to withdrawal from atezolizumab	0 (0)
Grade 3 AEs occurring in >5% of patients	%
Diarrhoea	9
Efficacy endpoints	
ORR, % (95% CI)	17 (5.0, 38.8)
mDOR, months (range)	NR (5.4–11.1+)
mPFS, months (95% CI)	2.3 (1.8, 9.5)
mOS, months (95% CI)	NE (6.5, NE)
6-month OS, % (95% CI)	72 (0.52, 0.93)

Bendell J, et al. Ann Oncol 2016; 27 (suppl 2): abstr LBA-01

LBA-01: Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC) – Bendell J, et al

Key results (cont.)



Change in tumour burden

PD-L1 IHC status on tumour cells (TC) and tumour-infiltrating immune cells (IC) defined as: TC3 = TC \geq 50% PD-L1+ cells; IC3 = IC \geq 10% PD-L1+ cells; TC2 = TC \geq 5% and < 50% PD-L1+ cells; IC2 = IC \geq 5% and < 10% PD-L1+ cells; TC1 = TC \geq 1% and < 5% PD-L1+ cells; IC1 = IC \geq 1% and < 5% PD-L1+ cells; TC0 = TC < 1% PD-L1+ cells; IC0 = IC < 1% PD-L1+ cells. NA, not available; Efficacy-evaluable patients. 2 patients missing or unevaluable are not included. Data cut-off, February 12, 2016.

Bendell J, et al. Ann Oncol 2016; 27 (suppl 2): abstr LBA-01

LBA-01: Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC) – Bendell J, et al


Conclusions

- Cobimetinib + atezolizumab was well tolerated at a maximum administered doses in patients with chemorefractory KRAS mutant mCRC
- A higher clinical response rate in MSS patients was observed with the combination of cobimetinib + atezolizumab than would be expected from either cobimetinib or atezolizumab alone
- These results suggest that cobimetinib can sensitise tumours to atezolizumab by increasing MHC I expression on tumour cells and promoting intratumoral CD8 T cell accumulation
- Further analysis and a phase 3 study are ongoing

LBA-05: First-line FOLFOX-4 ± cetuximab in Chinese patients with RAS-wild-type (wt) metastatic colorectal cancer (mCRC): The openlabel, randomized phase 3 TAILOR trial – Liu T, et al

Study objective

 To assess the efficacy and safety of 1L cetuximab + FOLFOX-4 vs FOLFOX-4 alone in patients with RAS WT mCRC



PRIMARY ENDPOINT

• PFS (RECIST 1.0)

*Cetuximab 400 mg/m² D1 then 250 mg/m²/week; [†]oxaliplatin 85 mg/m² D1 q2w, 5FU 400 mg/m² bolus then 600 mg/m²/day continuous infusion D1,2 q2w, leucovorin 200 mg/m² D1,2 q2w.


SECONDARY ENDPOINTS

- OS, ORR
- Safety

Liu et al. Ann Oncol 2016; 27 (suppl 2): abstr LBA-05

LBA-05: First-line FOLFOX-4 ± cetuximab in Chinese patients with RAS-wild-type (wt) metastatic colorectal cancer (mCRC): The openlabel, randomized phase 3 TAILOR trial – Liu T, et al


Key results



*Log-rank test.

Liu et al. Ann Oncol 2016; 27 (suppl 2): abstr LBA-05

LBA-05: First-line FOLFOX-4 ± cetuximab in Chinese patients with RAS-wild-type (wt) metastatic colorectal cancer (mCRC): The openlabel, randomized phase 3 TAILOR trial – Liu T, et al



*Log-rank test; †Fisher exact test.

Liu et al. Ann Oncol 2016; 27 (suppl 2): abstr LBA-05

LBA-05: First-line FOLFOX-4 ± cetuximab in Chinese patients with RAS-wild-type (wt) metastatic colorectal cancer (mCRC): The openlabel, randomized phase 3 TAILOR trial – Liu T, et al

Key results (cont.)

Grade ≥3 AEs in ≥10% of patients, n (%)	Cetuximab + FOLFOX-4 (n=194)	FOLFOX-4 alone (n=199)
Neutropenia	120 (61.9)	86 (43.2)
Leukopenia	52 (26.8)	42 (21.1)
Rash	27 (13.9)	0
Fatigue	25 (12.9)	19 (9.5)
Hypokalaemia	20 (10.3)	8 (4.0)
Thrombocytopenia	20 (10.3)	13 (6.5)


Conclusions

- This study confirms cetuximab + FOLFOX-4 as a SoC 1L treatment for patients with RAS WT mCRC
- Cetuximab + FOLFOX-4 significantly improved PFS, OS + ORR vs FOLFOX-4 alone
- There were no new or unexpected safety findings
- Subgroup analyses are currently ongoing

O-011: Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO – Antoniotti C, et al

Study objective

 To evaluate the activity and safety of 1L mFOLFOXIRI + cetuximab and the role of maintenance using cetuximab or bevacizumab in patients with unresectable mCRC (initially KRAS WT patients, but after an amendment in October 2013, only RAS/BRAF WT)



PRIMARY ENDPOINT

• 10-month progression-free rate (PFR)

*Cetuximab 500 mg/m² + irinotecan 130 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2400 mg/m²over 48h q2w

SECONDARY ENDPOINTS

• Response, safety

O-011: Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO – Antoniotti C, et al

Key results

	Cetuximab (n=59)	Bevacizumab (n=57)
10-month progression free, n	26	23
Secondary resection rate, % R0/R1/R2 R0	45.8 32.2	29.8 22.8
Best response, % CR PR SD PD Not assessed ORR DCR	5 63 24 3 5 67.8 92	4 72 14 4 6 75.4 89

O-011: Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO – Antoniotti C, et al

Key results (cont.)

Grade 3/4 AEs occurring in >5% of patients, %	Cetuximab (n=59)	Bevacizumab (n=57)
Neutropenia	28.8	33.3
Diarrhoea	20.3	15.8
Skin rash	18.6	12.3
Asthenia	10.1	8.8
Stomatitis	6.8	5.3
Neurotoxicity	6.7	0

Conclusions

- The primary endpoint was not met in either of the two arms
- It is, however, feasible to use a 4-month induction with mFOLFOXIRI + cetuximab, with relevant activity, leading to high conversion rate which may positively affect OS results

O-023: Observational data outcomes of chemotherapy backbone for MSI-high metastatic colorectal cancer in molecular epidemiology of colorectal cancer study in Israel – Shulman K, et al

Study objective

 To evaluate the effectiveness of modern CT backbones and bevacizumab in the treatment of MSI mCRC

Study design

- Data on patients with MSI-high mCRC who were treated with a 1L CT with or without bevacizumab were extracted from the database of Israeli population-based CRC study*
- Patients were diagnosed in 1998–2010 and were followed up until December 2013
- MSI status was determined by comparing 10 molecular markers in tumour and normal tissue
- Date of metastases, death and treatment details were extracted from the oncological follow-up records supported by computerised pharmacy records

ENDPOINTS

- 5-year OS
- Disease-specific survival

*Molecular Epidemiology of Colorectal Cancer (MECC) study.

O-023: Observational data outcomes of chemotherapy backbone for MSI-high metastatic colorectal cancer in molecular epidemiology of colorectal cancer study in Israel – Shulman K, et al


Key results

		All (n=87)		BRAF-WT (n=69)	
OS by treatment		mOS, months	60-month OS %	mOS, months	60-month OS, %
5FU		18.5	10	24.2	13
Irinotecan + 5FU		17.2	11	20.0	14
Irinotecan + 5FU + bevac	izumab	13.8	6	21.9	8
Oxaliplatin + 5FU + beva	cizumab	24.2	31	20.2	33
OS by BRAF status	n	# Event	s HR	(95% CI)	p-value
MUT	17	17	1.9	(1.1, 3.3)	0.02
WT	69	56		-	-

Shulman et al. Ann Oncol 2016; 27 (suppl 2): abstr O-023

O-023: Observational data outcomes of chemotherapy backbone for MSI-high metastatic colorectal cancer in molecular epidemiology of colorectal cancer study in Israel – Shulman K, et al

Key results (cont.)



OS by MSI status + treatment (BRAF-WT tumours)

*All combinations vs 5FU only.

Shulman et al. Ann Oncol 2016; 27 (suppl 2): abstr O-023

O-023: Observational data outcomes of chemotherapy backbone for MSI-high metastatic colorectal cancer in molecular epidemiology of colorectal cancer study in Israel – Shulman K, et al

Key results (cont.)

OS by MSI status (BRAF WT)	Patients, n	MSI-H vs MSS HR (95% CI)	p-value*
5FU treatment only	165	0.53 (0.30, 0.92)	0.025
Pooled treatments	479	0.77 (0.59, 1.01)	0.062


Conclusions

- Patients with MSI-H mCRC represent a substantial and biologically distinct subset
- Patients with MSI-H tumours respond differently to 1L CT than patients with MSS tumours
- The treatment effect of modern CT protocols in MSI-H tumours is not statistically different from a simple 5FU effect
- It is possible that combination treatment with FOLFOX + bevacizumab has a more pronounced effect than other treatment regimens in MSI-H tumours
- MSS/BRAF-negative tumours have significant treatment benefit from 'modern' CT regimens compared with 5FU alone

O-026: Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): Phase 2 results – Tabernero J, et al

Study objective

• To evaluate the efficacy and safety of encorafenib + cetuximab ± alpelisib (a PI3K inhibitor), in patients with advanced BRAF-mutant CRC



PRIMARY ENDPOINT(S)

• PFS

*200 mg/day PO;

[†]400 mg/m² IV for first dose followed by 250 mg/m² weekly.

SECONDARY ENDPOINTS


- ORR, DCR, OS
- Safety

Tabernero et al. Ann Oncol 2016; 27 (suppl 2): abstr O-026

O-026: Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): Phase 2 results – Tabernero J, et al

Key results

PFS



Time since 1st dose, months

Tabernero et al. Ann Oncol 2016; 27 (suppl 2): abstr O-026

O-026: Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): Phase 2 results – Tabernero J, et al

Key results (cont.)

HR for the triplet vs doublet regimen: 1.1 (95% Cl 0.6, 2.0) 100 Censoring times 80 Triplet regimen Probability, % **Doublet regimen** 60 · 40mOS, months (95% CI) Triplet regimen 13.1 (7.7, NE) +++ 20-Doublet regimen 12.4 (7.6, NE) 0 2 10 12 18 0 Δ 6 8 14 16 20

Time since randomisation, months

Response	Triplet regimen (n=52)	Doublet regimen (n=50)
ORR, % (95% CI)	27 (16, 41)	22 (12, 36)
DCR, % (95% CI)	85 (72, 93)	84 (71, 93)
mDOR, months (95% CI)	9.9 (2.8, 11.0)	4.6 (2.0, 6.7)

*With 44 events. NE, not estimable.

Tabernero et al. Ann Oncol 2016; 27 (suppl 2): abstr O-026

OS (interim analysis)*

O-026: Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): Phase 2 results – Tabernero J, et al

Key results (cont.)

Grade 3–4 AEs in ≥10% of patients, %	Triplet regimen (n=52)	Doublet regimen (n=50)
Any	79	62
Abdominal pain	10	8
Hyperglycaemia	13	2
Anaemia	17	6
Increased lipase	8	22

Conclusions

- Encorafenib + cetuximab ± alpelisib showed promising clinical activity in patients with advanced BRAF-mutant CRC, with improved survival vs historical data (not shown)
- Alpelisib added to encorafenib + cetuximab may improve PFS vs encorafenib + cetuximab alone
- Both regimens were generally well tolerated
 - AEs were more frequent with the triplet regimen
- Results of planned PK/PD and biomarker analyses may help interpret the efficacy and safety data

Study objective

 To evaluate a novel anti-IL-1 alpha antibody therapy in patients with advanced CRC and multiple symptoms known to inversely correlate with OS


Key patient inclusion criteria

- mRC
- Refractory to standard chemotherapy including Oxaliplatin and Irinotecan
- Other symptoms/functional impairment (pain, fatigue, anorexia, ECOG PS 1/2), weight loss or elevated systemic inflammation

(n=309)

PRIMARY ENDPOINT

 OR using dual-energy X-ray absorptiometry and EORTC-QLQC30



SECONDARY ENDPOINTS

 Pharmacodynamics measures known to co-relate with survival, safety, PD

Hickish et al. Ann Oncol 2016; 27 (suppl 2): abstr O-027

Key results

Primary endpoint	MABp1 (n=207)	Placebo (n=102)	p-value
Clinical response rate, %	33	19	0.0045


- Compared with placebo, relative risk SAEs reduced by 26% in MABp1-treated patients
- 5-fold improvement in platelet counts compared with placebo
- Higher incidence of SD of 53% in MABp1-treated patients

Objective measures	Non- responders	Responders	p-value
Lean body mass, kg	0.072	1.41	0.0007
Paraneoplastic thrombocytosis, 1000/mm ³	33.3	-2.0	0.0002
Systemic inflammation (serum IL-6), pg/mL	10.3	-3.38	0.0007

Key results (cont.)

Self-reported outcomes	Non-responders	Responders	p-value
Global QoL	-6.98	4.32	<0.001
Role function	-13.43	3.87	<0.001
Emotional function	-2.33	10.03	<0.001
Social function	-6.71	10.16	<0.001
Pain	16.19	-12.66	<0.001
Fatigue	13.08	-10.85	<0.001
Anorexia	17.34	-13.80	<0.001
SD (8 weeks), %	11.7	24.1	0.006
Incidence of SAEs (8 weeks), %	29.3	5.7	<0.01

Key results (cont.)



Conclusion

• Antibody therapy with MABp1 significantly improved clinical response rates, which translated into substantial benefit in OS

SCREENING, BIOMARKERS AND PROGNOSTIC MARKERS

Colorectal Cancer

O-012: Prognosis of lung metastases in patients with metastatic colorectal cancer: An ARCAD meta analysis – Henriques J, et al

Study objective

• To assess lung metastases prognostic for OS in patients with mCRC

Study design

- First-line treatment clinical trials involving lung metastases were selected from the ARCAD (Aide et Recherche en Cancérologie Digestive) database
- OS was evaluated based on date of randomisation and date of death due to any cause; association of OS with lung metastases was investigated in the general population, and in two subgroups – those with one metastatic site and those with at least two metastatic sites
- A propensity score approach was performed to assess heterogeneity in term of baseline characteristics between patients with and without lung metastases

O-012: Prognosis of lung metastases in patients with metastatic colorectal cancer: An ARCAD meta analysis – Henriques J, et al

Key results					
	Patients, n	mOS, months	HR	95% CI	p-value
Overall population	17,102		0.85	0.82, 0.88	<0.0001
One metastatic site with lung	955	24.9		22.7, 27.2	
metastases			0.71	0.67, 0.75	< 0.0001
One metastatic site without lung metastases	6399	20.0		18.7, 21.6	
Two or more metastatic sites	5564	15.3		14.8, 16.0	
with lung metastases			0.94	0.90. 0.97	0.001
Two or more metastatic sites without lung metastases	4184	14.4		13.8, 15.0	

Conclusions

- -

- In patients with mCRC, lung metastases were associated with a longer OS
- This protective effect appeared to be more important in patients who had one metastatic site only

Note: Based on data from abstract only

Henriques et al. Ann Oncol 2016; 27 (suppl 2): abstr O-012

O-013: A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC) – Pietrantonio F, et al


Study objective

• To develop a tool (a nomogram) to predict probability of death within 12 weeks from the date of an investigator's assessment of refractory metastatic colorectal cancer (mCRC)

Study design

- Between 2001 and 2014, data from 515 patients with mCRC and ECOG PS ≤2 were collected at 8 Italian institutions
- Refractoriness was defined as progressive disease during or within 12 weeks following the last administration of approved standard therapies including fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab or panitumumab if (K)RAS wild type, or unacceptable toxicity
- A nomogram for predicting the probability of death within 12 weeks was built by processing the prognostic variables in a random Forest model
- The variables were selected based on the RI statistical significance, obtained by permuting the response variable and the final nomogram was built using a binary logistic model including only the significant variables
- The prognostic variables of interest were: sex, age, primary tumour site, tumour resection, synchronous metastases, number and sites of metastases, ECOG PS, carcinoembryonic antigen, platelets, leukocytes, haemoglobin, neutrophils/lymphocytes ratio, sodium, alkaline phosphatase, lactate dehydrogenase, time interval between metastatic diagnosis and refractoriness, number of previous treatment lines, and RAS and BRAF mutational status

O-013: A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC) – Pietrantonio F, et al



O-013: A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC) – Pietrantonio F, et al

Key results (cont.)

• Results obtained in the developing set (n=411) were reproduced in the validation set (n=359)

	Developing set Validation set	
	(n=411)	(n=359)
Hosmer-Lemeshow test	p=0.117	p=0.0001
Harrell C index (95% CI)	0.778 (0.730, 0.824)	0.722 (0.717, 0.824)

Conclusions

- Four patient characteristics/clinical parameters (ECOG PS, resection, lactate dehydrogenase and peritoneal metastases) can be used to predict the probability of death within 12 weeks in patients with refractory mCRC
- The model developed is reliable and the results obtained in the developing set have been adequately reproduced in the validating set
- This nomogram may significantly improve the selection of later lines of therapy for patients with mCRC in the daily clinical practice
 - It may also assist researchers in determining life expectancy to ensure consistency of enrolment in early phase clinical trials

O-014: Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: Results of the SIRFLOX study – Heinemann V, et al


Study objective

To evaluate the depth of response with 1L mFOLFOX6 (+ bevacizumab at investigator's discretion) + SIRT using Y-90 resin microspheres compared with mFOLFOX6 (± bevacizumab) in patients with mCRC



- Non-resectable liver-only or liver-dominant mCRC
- No prior chemotherapy
- WHO PS 0-1

(n=530)



ENDPOINTS

• Depth of response using novel volumetric model; association between tumour shrinkage with baseline tumour burden

SIRT, selective internal radiation therapy; *investigator's discretion.

Heinemann et al. Ann Oncol 2016; 27 (suppl 2): abstr O-014

O-014: Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: Results of the SIRFLOX study – Heinemann V, et al

Key results

	SIRT + mFOLFOX6 (± bevacizumab) (n=251)	mFOLFOX6 (± bevacizumab) (n=235)	p-value
All patients Median baseline volume, cm ³ (IQR) Mean depth of response, % (SD) Median time to nadir, days (IQR)	219.4 (451.7) -75.0 (61.3) 266 (238)	166.6 (427.7) -67.8 (82.9) 206 (187)	0.421 0.039 <0.001
Tumour burden ≤12% Median baseline volume, cm ³ (IQR) Mean depth of response, % (SD) Median time to nadir, days (IQR) Median hepatic PFS, months	61.3 -72.5 (82.3) 243.5 (211) 15.1	68.4 (87.6) -80.6 (34.0) 220 (193) 12.2	0.912 0.763 0.152 0.112
Tumour burden >12% Median baseline volume, cm ³ (IQR) Mean depth of response, % (SD) Median time to nadir, days (IQR) Median hepatic PFS, months	512.0 (713.7) -77.5 (29.2) 298 (246) 27.2	439.9 (590.1) -57.2 (109.2) 196 (176) 13.1	0.188 0.003 <0.001 0.003

IQR, interquartile range; SD, standard deviation.

Heinemann et al. Ann Oncol 2016; 27 (suppl 2): abstr O-014

O-014: Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: Results of the SIRFLOX study – Heinemann V, et al


Conclusions

- Hepatic depth of response was significantly greater in patients receiving SIRT using Y-90 microspheres compared with chemotherapy
- Patients with a baseline tumour burden of >12% had a significantly longer PFS in the liver as first event with SIRT, while those with tumour burden ≤12% had a greater impact on CR rate
- This may provide a useful predictor of PFS in the liver

O-015: Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study – Cheng A-L, et al

Study objective

 To evaluate the association between depth of response and PFS and OS in the RAS-WT population from the APEC study



PRIMARY ENDPOINT(S)

• Depth of response (defined as the extent of maximal tumour shrinkage)

SECONDARY ENDPOINTS

• PFS, OS, ORR, safety

O-015: Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study – Cheng A-L, et al

Key results

	Overall	Cetuximab + FOLFOX	Cetuximab + FOLFIRI
ORR, %	64.7	62.7	68.4
mPFS, months	13.0	13.3	12.8
mOS, months	28.4	27.8	28.7
Median depth of response, % (IQR)	62.2 (39.1–80.0)	62.2 (40.0-80.7)	62.5 (38.1–79.0)
Median time to tumour size nadir, months (95% CI)	5.9 (5.6, 7.6)	5.9 (5.6, 7.6)	7.4 (5.1, 9.2)

O-015: Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study – Cheng A-L, et al

Conclusions

- These findings compare favourably to earlier subgroup analyses of analogous pivotal studies involving chemotherapy + weekly cetuximab
- Depth of response seems to be a sensitive indicator of response and is likely to be associated with PFS and OS
- The phase 2 APEC study suggests that patients with RAS-WT mCRC may benefit from continuation treatment with FOLFOX or FOLFIRI + cetuximab rather than having treatment breaks to achieve maximum tumour reduction

O-016: A prognostic marker for colorectal cancer: Combining analyses of ploidy and stroma – Fotheringham S, et al

Study objective

 To evaluate the prognostic value of DNA ploidy and tumour stroma in patients with early stage CRC

Study design


- Analysis of DNA content (ploidy) and stroma-tumour fraction was performed using automated digital imaging systems on FFPE tissue samples from 1074 patients enrolled in the QUASAR2 trial*
- Key inclusion criteria:
 - Stage III or high risk Stage II patients with CRC
 - Complete resection with no evidence of residual disease
- Ploidy digital analyses
 - Sample classified as diploid (low risk) when DNA content 2N
 - Sample classified as tetraploid (non-diploid; high risk) when DNA content 4N or higher
- Stroma digital analyses
 - The percentage of stroma tissue was determined by H&E staining
 - Stroma high: ≥50% (high risk)
 - Stroma low: <50% (low risk)

*Explored adjuvant capecitabine + bevacizumab.

Fotheringham et al. Ann Oncol 2016; 27 (suppl 2): abstr O-016

O-016: A prognostic marker for colorectal cancer: Combining analyses of ploidy and stroma – Fotheringham S, et al

Key results (cont.)



Fotheringham et al. Ann Oncol 2016; 27 (suppl 2): abstr O-016

O-016: A prognostic marker for colorectal cancer: Combining analyses of ploidy and stroma – Fotheringham S, et al

Conclusions

- High risk Stage II patients with CRC can be divided into risk groups based on a combination of measurements of DNA ploidy and stroma
- Automated digital pathology could facilitate the adoption of biomarker analyses into patient treatment strategies
- Additional trial samples (n=2500) will confirm results in a larger patient population
- The ultimate aim is to develop a prognostic test that can be offered to patients to help inform the use of adjuvant treatment after surgery

O-017: Can single nucleotide variants in TGFBR1 and SMAD7 modify colorectal screening recommendations? – Mahon GAT, et al

Study objective

• To investigate the role of blood-based genetic markers in CRC pre-screening

Study design

- Blood samples were taken from 187 patients with CRC and 94 healthy controls from a European Caucasian population
- After gDNA extraction, selected sequences were amplified by PCR followed by melting curve analysis
- The SNP status for TGFBR1 (rs334348) and SMAD7 (rs4939827) was determined for each subject
- The association between allele frequency for the various SNPs and CRC status was evaluated by logistic regression

PRIMARY ENDPOINT(S)

 An index was developed to distinguish high-risk from low-risk subjects

SECONDARY ENDPOINTS

• Various thresholds of the index were investigated to optimise the economic performance of the test for various relative costs of false positives or false negatives

Note: Based on data from abstract only

Mahon et al. Ann Oncol 2016; 27 (suppl 2): abstr O-017

O-017: Can single nucleotide variants in TGFBR1 and SMAD7 modify colorectal screening recommendations? – Mahon GAT, et al

Key results

- A highly significant additive association between the G allele and colorectal cancer for TGFBR1 was observed
 - Both the AG (heterozygosity) and GG (homozygosity) genotypes were associated with progressively greater risk relative to the AA genotype (OR 3.43; p<0.00005)
 - There was no further significant effect for dominance (OR 0.70; p=0.216)
- Although there was no significant additive effect, i.e. the risks associated with the CC and TT genotypes were similar (OR 1.00; p=0.987) for SMAD7, there was a significant dominance effect and the CT heterozygote was associated with a lower risk (OR 0.50; p=0.014)
- Sensitivity was calculated as the ratio of test-positive cases to total cases, and specificity as the ratio of test-negative controls to total controls
- The trade-off between specificity and sensitivity was explored by ROC analysis
 - When sensitivity was 0.33, specificity was 0.96; when sensitivity was 0.65, specificity was also 0.65; and when sensitivity was 0.87, specificity was 0.33

ROC, receiver operating characteristic.

O-017: Can single nucleotide variants in TGFBR1 and SMAD7 modify colorectal screening recommendations? – Mahon GAT, et al

Conclusions

- These results suggest that by being able to predict a clearly higher risk group, a repeat colonoscopy could be performed earlier than stated by guidelines for these individuals
- This inexpensive germline test, which only needs to be performed once, can be carried out at any age, including much earlier than is recommended by current guidelines

O-018: Clinical application of targeted next generation sequencing for colorectal cancer patients: A multicentric Belgian experience – Fontanges Q, et al

Study objective

• To examine 3 years of clinical experience of using NGS for assessing CRC-associated molecular alterations

Study design

- Mutations in 22 cancer-related genes can be detected using the Ion Torrent AmpliSeq colon/lung cancer panel; this was used prospectively in clinical practice via the BELAC ISO 15189 accredited method
- DNA from FFPE material of 741 colorectal tumours, including primary tumours and metastasis, was obtained from 14 different institutions, and subjected to targeted NGS using the Ion Torrent Personal Genome Machine

O-018: Clinical application of targeted next generation sequencing for colorectal cancer patients: A multicentric Belgian experience – Fontanges Q, et al

Key results

- Mean (range) number of mutations per tumour was 1.6 (0–5)
- At least one mutation was observed in 650 (89.4%) samples
 - The most frequent were TP53 (61.8%) and KRAS (46.1%)

Conoc	Samples with mutations, %			
Genes	This study	cBioPortal database		
KRAS	46.1	42–55		
NRAS	4.4	2.8–9		
BRAF	10.7	4.3–9.9		
PIK3CA	13.8	14.8–30.6		
ERBB2 Mutation Amplification	0.4 0.3	2.8–4 3.1		
AKT1	0.1	0.9–1.4		

Fontanges et al. Ann Oncol 2016; 27 (suppl 2): abstr O-018

O-018: Clinical application of targeted next generation sequencing for colorectal cancer patients: A multicentric Belgian experience – Fontanges Q, et al

Conclusions

 The results demonstrate that the AmpliSeq colon/lung cancer panel can be used routinely in clinical practice to provide reliable clinically relevant information for patients with colorectal cancer, which can used to facilitate therapeutic decisions in these patients

Study objective

 To assess the effectiveness of RAS status testing using ctDNA vs SoC to establish eligibility for anti-EGFR therapy in patients with mCRC

Study design

 RAS status was assessed using BEAMing assays on plasma and FFPE tumour tissue or SoC RAS testing using qPCR or pyrosequencing on FFPE tumour tissue, in 147 patients with mCRC

	SoC tumour	BEAMing tumour	BEAMing plasma
RAS testing sensitivity, %	1–5	1	0.02-0.04

PRIMARY ENDPOINT

Concordance rate for RAS testing

SECONDARY ENDPOINT

• PFS, OS

Key results

Concordance analysis		BEAMing	plasma
		RAS MUT	WT
SoC tumour	RAS MUT	49	5
	WT	10	83
	Total	59	88

• Overall concordance: 89.8%; Kappa index 0.81 (95% CI 0.71, 0.90)

RAS mutant: 40.1% with BEAMing plasma vs 36.7% with SoC tumour

Discordance analysis: mutations detected only in tumour						
SoC tumour	BEAMing plasma	BEAMing tumour	Codon	Prior CT lines	Possible explanation	
MUT	WT	MUT	KRAS G12	0	Low tissue burden*	
MUT	WT	MUT	KRAS G12	2	Low lissue builden	
MUT	WT	MUT	KRAS G12	0	otDNA shadding	
MUT	WT	MUT	NRAS G13	0	ctDNA shedding	
MUT	WT	WT	KRAS Q61	0	Molecular heterogeneity	

*Few hepatic metastases <1 cm, 3 small peritoneal implants.


Grasselli et al. Ann Oncol 2016; 27 (suppl 2): abstr O-024

Key results (cont.)

Discordance analysis: mutations detected only in plasma					
SoC tumour	BEAMing plasma	BEAMing tumour	Codon	Prior CT lines	Possible explanation
WT	MUT	MUT	KRAS G12	2	
WT	MUT	MUT	KRAS A146	0	
WT	MUT	MUT	KRAS A146	0	SoC sensitivity
WT	MUT	MUT	NRAS Q61	1	
WT	MUT	MUT	NRAS Q61	0	
WT	MUT	WT	KRAS G12	1	
WT	MUT	WT	KRAS G12	0	
WT	MUT	NA	KRAS Q61	2	Molecular heterogeneity
WT	MUT	WT	KRAS Q61	0	neterogeneity
WT	MUT	WT	NRAS Q61	1	

2L + 3L RAS WT	SoC tumour (n=51)	BEAMing plasma (n=47)
mPFS, months (95% CI)	8.7 (6.43, 10.23)	8.7 (6.77, 11.27)

Grasselli et al. Ann Oncol 2016; 27 (suppl 2): abstr O-024



Conclusions

- A concordance rate of 89.8% was achieved between ctDNA RAS testing and standard tissue testing in patients with mCRC eligible for anti-EGFR therapies
- Plasma RAS testing by BEAMing captures a population responding to anti-EGFR therapy with the same precision as that of SoC RAS testing in tumours
- Discordant samples could be explained by technical sensitivity, temporal or spatial heterogeneity and low tumour burden
- The feasibility and practicability of ctDNA analysis may significantly influence clinical practice for anti-EGFR treatment selection

NR, not reached.

Grasselli et al. Ann Oncol 2016; 27 (suppl 2): abstr O-024

Colorectal Cancer

COLON CANCER

O-010: An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial – Eto T, et al

Study objective

• To evaluate the compliance and safety of the phase 3 ACHIEVE trial

Study design

- Patients with Stage III colon cancer (n=1313)
- Patients received 3 months (n=651) or 6 months (n=650) of oxaliplatin-based adjuvant treatment (mFOLFOX6 or XELOX)

O-010: An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial – Eto T, et al

Key results

	3 months		6 mc	onths	
	mFOLFOX6	XELOX	mFOLFOX6	XELOX	
Compliance, %	87.6	69.6	85.9	58.7	
Permanent discontinuation due to toxicity, %	11.5		28.7		
Grade 3/4 AEs, %	28.7		42.8		
Grade ≥2 neuropathy, %	13.6		36.5		
Grade 3/4 AEs, %		mFOLFOX6		XELOX	
Neutropenia		30.4 12.4		12.4	
Anorexia		1.9 5.1		5.1	
Diarrhoea		1.3	1.3 5.5		

Note: Based on data from abstract only

Eto et al. Ann Oncol 2016; 27 (suppl 2): abstr O-010

O-010: An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial – Eto T, et al

Conclusions


- mFOLFOX6 and XELOX were both safe and well tolerated
- There was, however, a difference in the grade 3–4 toxicities based on the 5FU backbone with patients in the 6-month arm having significantly higher rates than the 3-month arm
- In addition, compliance was better in the 3-month arm

Colorectal Cancer

RECTAL CANCER

Study objective

• To investigate the effect of adding oxaliplatin to preoperative 5FU-based pelvic chemoradiation (RT) in patients with resectable locally advanced rectal cancer (LARC)



PRIMARY ENDPOINT



*Infused 5FU (225 mg/m²/day) + external-beam pelvic radiation (50.4 Gy in 28 daily fractions) + weekly oxaliplatin (60 mg/m² x 6); *Infused 5FU (225 mg/m²/day) + external-beam pelvic radiation (50.4 Gy in 28 daily fractions).


SECONDARY ENDPOINTS

Cumulative incidence of distant metastasis

Lonardi et al. Ann Oncol 2016; 27 (suppl 2): abstr O-019

Key results


• As of 31 December 2015, there were 248 deaths, median follow-up was 8.9 years (interquartile range 8.1–9.9) and 94.3% of patients had received ≥90% of expected follow-up



Lonardi et al. Ann Oncol 2016; 27 (suppl 2): abstr O-019

Key results (cont.)

 Significantly more patients in the 5FU + RT group had metastases at time of surgery (n=16, 4.2%) than patients in the 5FU + RT + oxaliplatin group (n=2, 0.5%; p=0.001)



Distant metastases – cumulative incidence

Distant metastases – time course of HR

Lonardi et al. Ann Oncol 2016; 27 (suppl 2): abstr O-019

Key results (cont.)

Cause of death, n (%)	5FU + RT	5FU + RT + oxaliplatin
Disease	92 (24.4)	77 (21.3)
Toxicity	1 (0.2)	2 (0.5)
Other	29 (7.7)	24 (6.6)
Unknown	14 (3.7)	9 (2.5)
Overall	136 (36.1)	112 (30.9)


Conclusions

- These results indicate a small and sustained impact on the development of distant metastases; although not statistically significant, these results support the study hypothesis of the systemic effect of weekly oxaliplatin concomitant to preoperative chemoradiation
- This difference is paralleled by a smaller than planned reduction in the relative risk of death with a long-term benefit of 3% (5-year) to 6% (8-year)

O-020: Impact of surgical site experience on treatment outcomes of fixed-cT3 and cT4 rectal cancer patients in phase III study comparing preoperative radiochemotherapy and short-course radiotherapy with consolidation chemotherapy (Polish-II study) – Wyrwicz L, et al

Study objective

• To investigate if the experience of surgical centre has any influence on the outcomes of conventional radiotherapy in patients with locally advanced rectal cancer



ENDPOINTS

• RFS, OS (reported previously)

*3 cycles of 5FU/leucovorin + oxaliplatin in FOLFOX4 regimen.

Note: Based on data from abstract only

Wyrwicz et al. Ann Oncol 2016; 27 (suppl 2): abstr O-020

O-020: Impact of surgical site experience on treatment outcomes of fixed-cT3 and cT4 rectal cancer patients in phase III study comparing preoperative radiochemotherapy and short-course radiotherapy with consolidation chemotherapy (Polish-II study) – Wyrwicz L, et al

Key results

- R0 resection rate was improved in high volume vs low volume centres (80% vs 72%)
- After 3 years of follow-up, OS was significantly higher in those receiving SCRTx (78%) than those receiving CRTx (64%; p<0.05)
- Proportion of patients alive after 5 years was 75% and 60% in those receiving SCRTx and CRTx, respectively
- No differences in R0 resection rates (p=0.54) or OS (p=0.718) were observed in patients treated in low volume centres


O-020: Impact of surgical site experience on treatment outcomes of fixed-cT3 and cT4 rectal cancer patients in phase III study comparing preoperative radiochemotherapy and short-course radiotherapy with consolidation chemotherapy (Polish-II study) – Wyrwicz L, et al

Conclusions

- The combination of short-course radiotherapy + consolidation chemotherapy is an effective treatment in patients with locally advanced rectal cancer
- In experienced colorectal surgery centres, it improves survival compared with preoperative chemoradiation
- However, a longer follow-up is required to confirm the higher survival rates without significant improvement in the local control

Study objective

 To evaluate the feasibility of a tailored management of locally advanced rectal carcinoma (LARC) according to the early tumour response to a short and intensive induction triplet chemotherapy, while respecting a minimal 90% R0 resection rate in all arms



• Safety, efficacy

Cap, capecitabine.

Arm A

Key results

• A comparison of baseline patient characteristics revealed differences between good responders and poor responders

	Good responders		Poor res	ponders
	Arm A n=11	Arm B: Cap 50 n=19	Arm C: Cap 50 n=52	Arm D: Cap 60 n=51
Female sex, n (%)	6 (54.5)	8 (42.1)	18 (34.6)	11 (21.6)
Median (range) age, years	66.0 (44–78)	63.0 (39–75)	61 (22–82)	62 (22-80)
Median (range) BMI, kg/m ²	25.3 (18.5–33.6)	24.6 (16.9–32.5)	25.4 (16.9–34.0)	25.5 (18.3–41.3)
Tumour topography LP-LA, cm Median (range)	1.5 (0–5.8)	0 (0–10)	3.3 (0–11)	2.2 (0–44)
Circumference ≥50%, n (%)	6 (66.7)	6 (50.0)	35 (94.6)	26 (74.3)
Tumour volume, cm ³ Median (range)	23.0 (3.0–148)	22.0 (10.0–57.4)	43.0 (8.3–387)	47.4 (3.3–312)
CRM, mm Median (range)	1.0 (0–3)	0 (0–5)	0 (0–20)	0 (0–5)
EMS, mm Median (range)	6.0 (3.0–11.0)	4.0 (1.0–16.0)	10.0 (1.5–40.0)	12.0 (0.5–50.0)

CRM, circumferential resection margin,

EMS, extramural tumour spread.

Rouanet et al Ann Oncol 2016; 27 (suppl 2): abstr O-021

Key results (cont.)

 Toxicities to induction chemotherapy were observed in a greater proportion of good responders than poor responders; proportion of patients with grade 3–4 toxicities in groups A, B, C and D were 63.6%, 42.1%, 36.5% and 15.7%

	Good responders		Poor responders	
	Arm A (n=11)	Arm B: Cap 50 (n=19)	Arm C: Cap 50 (n=52)	Arm D: Cap 60 (n=51)
No surgery				
Progressive disease	0	0	0	3
Patient's withdrawal	1	0	0	1
Non-compliance	0	0	0	1
Resection R0				
n (%)	10 (100.0)	19 (100.0)	43 (82.7)	4 (87.8)
90% CI	(74, 100)	(85, 100)	(72, 91)	(77, 95)
R1	0	0	9 (17.3)	2 (4.1)
Peritoneal carcinomatosis	0	0	0	1 (2.0)
Progressive disease	0	0	0	3 (6.1)

CRM, circumferential resection margin.

Key results (cont.)

- Efficacy according to CRM
 - 111 predictive + CRM ≥ 103 CRM >1; efficacy: 93%
 - Arm C is the less effective group;
 13% failure

CRI	Μ	Predictive CRM	CRM on pa ≤1	thology >1
Arm A	≤1	7	0	7
	>1	2	0	2
Arm B	≤1	18	0	18
	>1	1	0	1
Arm C	≤1	46	6	40
	>1	5	0	5
Arm D	≤1	40	2	38
	>1	4	0	4
Total	≤1	111	8	103
	>1	12	0	12

Conclusions

- These preliminary results indicate that tailored management of rectal cancer based on early tumoral response to an inductive treatment is feasible
- By evaluating response early following neoadjuvant chemotherapy, good responders can be discriminated from poor responders without adverse effects on the curative resection rate
- Further long-term oncological and functional data is required to confirm this strategy

CRM, circumferential resection margin.

ANAL CANCER

Study objective

 To assess the safety and toxicity of nivolumab in patients with previously treated metastatic SCCA

Key patient inclusion criteria

- Metastatic SCCA
- ≥1 prior therapy, but immunotherapy naïve
- Presence/absence of PD-L1 expression
- ECOG PS 0-1 (n=39)

PRIMARY ENDPOINT

• ORR (RECIST 1.1)


Nivolumab 3 mg/kg IV q2w (n=37, toxicity; n=34, efficacy)

PD


SECONDARY ENDPOINTS

• PFS, safety

Key results



Response rate, n (%)				
CR	2 (5.4)			
PR	7 (18.9)			
SD	17 (45.9)			
PD	8 (21.6)			
Unevaluable	3 (8.1)			
ORR (ITT, n=37)	9 (24.3)			
ORR (evaluable, n=34)	9 (26.4)			



Patients with metastatic SCCA (n=37)	Treatment-related grade 3 AEs, %
Anaemia	5
Fatigue	3
Hypothyroidism	3
Rash	3

Eng et al. Ann Oncol 2016; 27 (suppl 2):,abstr O-022

Key results (cont.)

Gene	Туре	Incidence, n (%)
p53	Mutation	12 (46)
PIK3CA	Mutation	5 (19)
PIK3CA	Amplification	3 (12)

 No predictive correlation of cfDNA was observed for responders compared with non-responders and no prognostic correlation was identified

Conclusion

• Nivolumab monotherapy was well tolerated and the primary endpoint (ORR) was met